VCM
ODT

Versant Capital Management’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Versant Capital Management’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-9
Closed – – 1812
2019
Q4 		$0 Buy
+9
New +$279 ﹤0.01% 1674

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Versant Capital Management's ODT Position: Q1 2020 in Review

Versant Capital Management sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2020, closing a stake of 9 shares.

Versant Capital Management first reported a position in ODT in Q4 2019 and held it in 1 quarter. The position peaked at $0 in Q4 2019. 78 funds tracked by Wall St. Rank hold ODT as of Q1 2020.

  • Versant Capital Management reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Versant Capital Management sold 9 Odonate Therapeutics, Inc. Common Stock shares in Q1 2020.
  • Versant Capital Management first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • Versant Capital Management's Odonate Therapeutics, Inc. Common Stock position peaked at $0 in Q4 2019.
  • 78 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Versant Capital Management's 13F filing for Q1 2020, filed 17 Apr 2020.